Overall survival estimates among recent cohorts stratified by donor type
| Donor . | AML02 . | Total Therapy 15 . | ||||
|---|---|---|---|---|---|---|
| N . | 1-year OS (95% CI), % . | 5-year OS (95% CI), % . | N . | 1-year OS (95% CI), % . | 5-year OS (95% CI), % . | |
| Sibling | 14 | 93 (59-99) | 68 (25-90) | 10 | 80 (41-95) | 69 (31-89) |
| Unrelated | 21 | 74 (48-88) | 74 (48-88) | 19 | 60 (34-79) | 46 (21-68) |
| Haploidentical | 11 | 90 (47-99) | 77 (35-94) | 8 | 100 (100-100) | 100 (100-100) |
| Combined | 46 | 84 (69-92) | 74 (56-86) | 37 | 75 (57-86) | 65 (46-78) |
| Donor . | AML02 . | Total Therapy 15 . | ||||
|---|---|---|---|---|---|---|
| N . | 1-year OS (95% CI), % . | 5-year OS (95% CI), % . | N . | 1-year OS (95% CI), % . | 5-year OS (95% CI), % . | |
| Sibling | 14 | 93 (59-99) | 68 (25-90) | 10 | 80 (41-95) | 69 (31-89) |
| Unrelated | 21 | 74 (48-88) | 74 (48-88) | 19 | 60 (34-79) | 46 (21-68) |
| Haploidentical | 11 | 90 (47-99) | 77 (35-94) | 8 | 100 (100-100) | 100 (100-100) |
| Combined | 46 | 84 (69-92) | 74 (56-86) | 37 | 75 (57-86) | 65 (46-78) |
OS indicates overall survival.